drugset / Trial / NCT01207414

Switching to Iloperidone From Other Antipsychotics in Schizophrenia

NCT01207414

Phase 4 Completed 501 enrolled Novartis
RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluate the clinical outcome of two switching strategies to iloperidone treatment in adult subjects with schizophrenia who require a change in their current antipsychotic treatment of risperidone, olanzapine, or aripiprazole due to suboptimal efficacy and/or safety/tolerability reasons.

Timeline

Start
2010-08
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Iloperidone Small molecule 12 mg Oral
Subject Iloperidone Small molecule 24 mg Oral

Indications